title: p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
abstract: OBJECTIVE
  Esophageal squamous cell carcinoma is generally sensitive to chemoradiotherapy (CRT), but some cases are not. Using a retrospective analysis, we aimed to identify the predictors of the response by esophageal squamous cell carcinoma to definitive CRT.
  
  
  METHODS
  The intensities of expression of p53, Ki67, Bcl-2, Bax, cyclin D1, VEGF, CDC25B, and metallothionein (MT) were evaluated immunohistochemically in the biopsy specimens obtained before CRT, and the intensities of their expression were tested for correlations with the clinical effects of CRT.
  
  
  RESULTS
  The esophageal squamous cell carcinomas with negative p53, positive CDC25B, and negative MT expression were found to be significantly more sensitive to CRT. In addition, p53 positivity and CDC25B positivity respond well to CRT.
  
  
  CONCLUSIONS
  Esophageal squamous cell carcinomas with negative p53, positive CDC25B, and negative MT expressions respond well to CRT. Even with p53 positivity, if with CDC25B positivity, CRT can be expected.
authors.affiliation: Department of Internal Medicine, Jichi Medical School Hospital, Yakushiji 3311, Minamikawachi-machi, Kawachi-gun, Japan. f-sunada@jichi.ac.jp
authors.forename: Fumiko
authors.initials: F
authors.lastname: Sunada
authors.forename: Masayuki
authors.initials: M
authors.lastname: Itabashi
authors.forename: Hisanao
authors.initials: H
authors.lastname: Ohkura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Okumura
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D018797:Cell Cycle Proteins / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008668:Metallothionein / Q000172:deficiency*; D008875:Middle Aged; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency*; D020687:cdc25 Phosphatases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D016159:Tumor Suppressor Protein p53; D008668:Metallothionein; C517008:CDC25B protein, human; D020687:cdc25 Phosphatases